PURPOSE: The sensitivity of lymph node excisional biopsy requires validation. Power Doppler ultrasound (US) helps predict the malignant status of lymphadenopathies. We used power Doppler US to select for biopsy the lymph node most suspected of malignancy. PATIENTS AND METHODS: One hundred fifty-two patients having lymphadenopathies with clinical suspicion of lymphoma were divided into two well-matched groups and randomly assigned to undergo either standard or powerDoppler US-directed lymph node excisional biopsy. RESULTS: Histology showed a malignancy in 64% of patients in the standard group (lymphoma, 49 patients; carcinoma, two patients) and in 87% of patients in the US-assisted group (lymphoma, 62 patients; carcinoma, one patient). There were significantly fewer biopsy-related complications in the assisted group than in the standard group. During the follow-up of the patients with lymph nodes reported as being reactive, 14 of 29 patients in the standard group were rebiopsied and were found to have lymphoma (13 patients) or carcinoma at the subsequent lymph node histology, whereas none of the patients in the assisted group (nine patients) required a second biopsy. Thus, biopsy provided false-negative results for malignancy in 21% of patients affected by lymphoma in the standard group and never in the assisted group (P <.01). CONCLUSION: Power Doppler US is an accurate tool for screening lymphadenopathies to be removed by excisional biopsy in patients with suspected lymphoma.
RCT Entities:
PURPOSE: The sensitivity of lymph node excisional biopsy requires validation. Power Doppler ultrasound (US) helps predict the malignant status of lymphadenopathies. We used power Doppler US to select for biopsy the lymph node most suspected of malignancy. PATIENTS AND METHODS: One hundred fifty-two patients having lymphadenopathies with clinical suspicion of lymphoma were divided into two well-matched groups and randomly assigned to undergo either standard or power Doppler US-directed lymph node excisional biopsy. RESULTS: Histology showed a malignancy in 64% of patients in the standard group (lymphoma, 49 patients; carcinoma, two patients) and in 87% of patients in the US-assisted group (lymphoma, 62 patients; carcinoma, one patient). There were significantly fewer biopsy-related complications in the assisted group than in the standard group. During the follow-up of the patients with lymph nodes reported as being reactive, 14 of 29 patients in the standard group were rebiopsied and were found to have lymphoma (13 patients) or carcinoma at the subsequent lymph node histology, whereas none of the patients in the assisted group (nine patients) required a second biopsy. Thus, biopsy provided false-negative results for malignancy in 21% of patients affected by lymphoma in the standard group and never in the assisted group (P <.01). CONCLUSION: Power Doppler US is an accurate tool for screening lymphadenopathies to be removed by excisional biopsy in patients with suspected lymphoma.
Authors: M Picardi; C Cavaliere; R Della Pepa; E Nicolai; A Soricelli; C Giordano; N Pugliese; M G Rascato; I Cappuccio; G Campagna; C Cerchione; E Vigliar; G Troncone; M Mascolo; M Franzese; R Castaldo; M Salvatore; F Pane Journal: Ann Hematol Date: 2021-04-28 Impact factor: 3.673
Authors: Novella Pugliese; M Di Perna; I Cozzolino; G Ciancia; G Pettinato; P Zeppa; V Varone; S Masone; C Cerchione; R Della Pepa; L Simeone; C Giordano; V Martinelli; C Salvatore; F Pane; M Picardi Journal: Ann Hematol Date: 2017-01-27 Impact factor: 3.673
Authors: Marco Picardi; Claudia Giordano; Novella Pugliese; Maria Esposito; Melania Fatigati; Francesco Muriano; Maria G Rascato; Roberta Della Pepa; Alessandro D'Ambrosio; Elena Vigliar; Giancarlo Troncone; Daniela Russo; Massimo Mascolo; Giovanni Esposito; Mariella Prastaro; Roberta Esposito; Carlo G Tocchetti; Rosa Fonti; Ciro Mainolfi; Silvana Del Vecchio; Fabrizio Pane Journal: Br J Haematol Date: 2022-07-12 Impact factor: 8.615